Chemistry: molecular biology and microbiology – Animal cell – per se ; composition thereof; process of... – Animal cell – per se – expressing immunoglobulin – antibody – or...
Reexamination Certificate
1991-09-25
2002-11-05
Beckerleg, A. M. S. (Department: 1632)
Chemistry: molecular biology and microbiology
Animal cell, per se ; composition thereof; process of...
Animal cell, per se, expressing immunoglobulin, antibody, or...
C435S325000, C435S320100, C435S242000, C530S387200, C530S387300
Reexamination Certificate
active
06475787
ABSTRACT:
The production of monoclonal antibodies using hybridoma cells is now well known in the art. Briefly, isolated antibody-producing lymphocytes from an immunized animal, typically a mouse, are fused with an immortalized cell line, and the resultant hybridomas are screened for the production of the desired monoclonal antibody. Such methods have been successfully used to produce a wide array of antibodies.
However, several inherent shortcomings limit the utility of such methods and the resultant monoclonal antibodies (MAbs). Foremost of those limitations is that the Mabs so produced are essentially murine in nature and reactivity. Use of murine MAbs in human patients, whether for diagnostic or perhaps especially for therapeutic or prophylactic use, incurs a risk of untoward antigenic response by the patient.
In order to avoid such antigenicity, genetically engineered antibodies have been produced which retain the specific antigen-binding domains of the parent murine antibody, while substituting corresponding human antibody domains for part or all of the remaining murine polypeptide regions. It is hoped that such antibodies will not prove antigenic in humans because of their greater resemblance to human antibodies.
Briefly, chimeric antibodies may be produced by isolating the MAb-encoding DNA sequences from a desired hybridoma, excising the portion of the murine DNA which is not required to encode the antigen-binding domains, and replacing such DNA sequences with corresponding human DNA sequences. This has been done in two alternative ways. Firstly, the complete murine variable or V region DNA of each chain can be appropriately joined to human constant or C region DNA sequences. The resultant DNAs encode polypeptides with a murine V and human C domains. Examples are provided by Morrison et al, 1984, Proc. Natl. Acad, Sci. USA 81:6851 and Liu et al, 1987, J. Immunol. 139:3521. The antibody V regions are known to encode the antigen-binding portions of the antibody, and the C regions encode the biological effector functions, such as complement fixation. In the second approach, the portions of the murine V regions thought to encode the ‘antigen-binding’ specificity, or complementarily-determining regions (CDRs) are identified, and the same CDRs are used to replace the human CDRs of human V regions linked to human C regions. These are ‘CDR-swap’ antibodies, and examples are provided by Jones et al, 1986, Nature 321:522; Verhoeyen et al, 1988, Nature 332:323; and Reichmann et al, 1988, Nature 332:323. The resultant DNAs obtained by either approach thus encode “humanized” heavy and light chains.
While such genetically engineered antibodies may overcome limitations on the use of murine MAbs, expression of the chimeric DNAs encoding such MAbs or even of cloned murine MAb genes is still problematic. In one approach the DNAs are introduced into murine hybridoma or myeloma cells for heterologous expression. However, such methods have met with only limited success, in large part because of the disappointingly low expression levels achieved thus far. Thus, a continuing need exists for a method for heterologous expression of antibody-encoding DNAs. One object of this invention is to provide an improved heterologous expression system for such DNAs which affords high levels of expression of antibodies, preferably chimeric antibodies.
Heterologous gene expression is typically accomplished by introducing the desired gene (or DNA encoding the desired protein) into a host cell in association with an amplifiable marker such as a gene encoding dihydrofolate reductase (DHFR). The transfected or transformed host cells are then iteratively subjected to increasing selective pressure such that the number of copies of the marker gene and the associated desired gene are increased. Where the marker is a DHFR gene, the selective agent is methotrexate (MTX), as is well known in the art. However, where heavy and light chain antibody genes are so introduced into a host cell, no practical method exists to ensure that both genes are appropriately amplified. It should be noted that if expression of one chain predominates, then the expression level of the other chain can limit the amount of antibody actually produced. Additionally, heavy chain expression in the absence of light chain expression may be deleterious to the producing cells. Heavy chain toxicity is discussed in Kohler, G, 1980, Proc. Natl. Acad. Sci. USA 77:2197 and Haas and Wabl, 1984, ibid. 81:7185.
We have found that high expression levels for antibodies depends in part on differentially amplifying the heavy and light chain DNAs to optimize the relative gene copy numbers of the heavy and light chain DNAs. In the practice of this invention, such optimization of relative gene copy number and thus the relative expression levels may be conveniently achieved by introducing the heavy chain and light chain DNAs respectively associated with different amplifiable markers, presumably into different chromosomal locations when the introduced DNA is chromosomally integrated. The heavy chain DNA and the light chain DNA are then separately amplified by application of selective conditions for the respective markers until appropriate optimization of gene expression is achieved.
By way of example, the heavy chain-encoding DNA may be linked to an adenosine deaminase (ADA) gene and the light chain-encoding DNA linked to a DHFR gene. Each of the antibody genes with its respective marker gene is then introduced into the host cells, preferably Chinese Hamster Ovary (CHO) cells by conventional methods. For example, each set of DNA may be introduced into separate CHO cells, e.g. by electroporation, and the resultant transformants fused. The ADA
+
, DHFR
+
CHO cells so obtained contain the heavy chain DNA associated with an ADA gene and the light chain DNA associated with a DHFR gene, each of which DNAs is then specifically amplified by treatment with iteratively increasing amounts of MTX (amplifies light chain DNA, but not heavy chain DNA) and 2′-deoxycoformycin (dCF, amplifies heavy chain DNA but not light chain DNA). During the course of amplification the host cells are analyzed for antibody production (by ELISA). Cells so amplified for optimized antibody production were found to produce MAbs which retained the specific hapten binding characteristics of the parental MAb and which bind complement. Expression levels of about 60 &mgr;g/10
6
cells/48 hrs have been obtained, which may be even further improved by additional rounds of amplification. So far as we are aware, efficient production of antibodies in non-lymphoid cells has never been demonstrated heretofore.
It should be noted that the DNAs encoding the respective chains may be cDNA or genomic DNA. It should also be noted that this invention should be useful for the production not just of cloned antibodies, but also of genetically engineered antibodies such as CDR-swapped antibodies as previously mentioned, and in addition, genetically engineered antibody fragments or derivatives such as F
V
, Fab, F(ab)′
2
fragments using truncated DNAs and chimeric proteins such as Fab-enzyme and Fab-toxin fusion proteins. Thus, this approach will also be of general value in the production of hetero-dimeric molecules, other than complete antibodies. Examples include other forms of genetically-engineered antibodies, such as Fab and F(ab)
2
′ forms, and antigen-binding portions, such as a Fab, linked to non-antibody peptide sequences. Examples of the genetic engineering of such molecules are found in Newberger et al, 1984, Nature 312:604; Skerra and Pluckthun, 1988, Science 240:1038; Better et-al, 1988, Science 240:1041 and Reichmann et al, 1988, J. Mol. Biol. 203:825.
DETAILED DESCRIPTION OF THE INVENTION
I. Production of hybridoma cells
Hybridoma cell lines producing a desired antibody may be produced by conventional methods such as the well known methods of Kohler and Milstein. Briefly, an animal, preferably a rodent such as a Balb/c mouse is immunized and later re-immunized (boosted) with the desired immuno
Kaufman Randal J.
Wood Clive R.
Beckerleg A. M. S.
Collazo Diana M.
Manspeizer David A.
Ryan M. Andrea
Wyeth
LandOfFree
Method for producing monoclonal antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for producing monoclonal antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for producing monoclonal antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2915430